Adler A, Bergwik J, Padra M, Papareddy P, Schmidt T, Dahlgren M
Respir Res. 2025; 26(1):101.
PMID: 40087604
DOI: 10.1186/s12931-025-03175-z.
Padmakumar L, Menon R, Gopala S, Vilanilam G
Acta Neurol Belg. 2025; .
PMID: 39960601
DOI: 10.1007/s13760-025-02747-6.
Valerie N, Sanjiv K, Mortusewicz O, Zhang S, Alam S, Pires M
Nat Commun. 2024; 15(1):10347.
PMID: 39643609
PMC: 11624193.
DOI: 10.1038/s41467-024-54415-7.
Taiyab A, Ashraf A, Sulaimani M, Rathi A, Shamsi A, Hassan M
Redox Biol. 2024; 77:103394.
PMID: 39418911
PMC: 11532495.
DOI: 10.1016/j.redox.2024.103394.
Janitri V, Aruljothi K, Ravi Mythili V, Singh S, Prasher P, Gupta G
MedComm (2020). 2024; 5(10):e745.
PMID: 39329017
PMC: 11424683.
DOI: 10.1002/mco2.745.
Tumor specimen cold ischemia time impacts molecular cancer drug target discovery.
von der Heyde S, Raman N, Gabelia N, Matias-Guiu X, Yoshino T, Tsukada Y
Cell Death Dis. 2024; 15(9):691.
PMID: 39327466
PMC: 11427669.
DOI: 10.1038/s41419-024-07090-x.
Hypoxia-Targeted Immunotherapy with PD-1 Blockade in Head and Neck Cancer.
Wakisaka R, Yamaki H, Kono M, Inoue T, Sato R, Komatsuda H
Cancers (Basel). 2024; 16(17).
PMID: 39272872
PMC: 11394489.
DOI: 10.3390/cancers16173013.
An Oxidative Stress Nano-Amplifier for Improved Tumor Elimination and Combined Immunotherapy.
Zhang W, Ran Y, Yang M, Hu Y, Wang Z, Cao Y
Adv Healthc Mater. 2024; 13(31):e2402349.
PMID: 39221686
PMC: 11650535.
DOI: 10.1002/adhm.202402349.
Crizotinib and its enantiomer suppress ferroptosis by decreasing PE-O-PUFA content.
Cen S, Lin F, Li X, Hu Y, Liu J, Xue Z
Cell Death Discov. 2024; 10(1):360.
PMID: 39134539
PMC: 11319649.
DOI: 10.1038/s41420-024-02127-8.
USP9X regulates the proliferation, survival, migration and invasion of gastric cancer cells by stabilizing MTH1.
Xu W, Zhang Y, Su Y, Li L, Yang X, Wang L
BMC Gastroenterol. 2024; 24(1):239.
PMID: 39075342
PMC: 11288101.
DOI: 10.1186/s12876-024-03321-9.
Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy.
Bayoumy A, Ansari A, Mulder C, Schmiegelow K, Florin T, De Boer N
Clin Pharmacokinet. 2024; 63(8):1089-1109.
PMID: 39031224
PMC: 11343975.
DOI: 10.1007/s40262-024-01393-0.
The interplay of DNA damage and repair, gene expression, and mutagenesis in mammalian cells during oxidative stress.
Besaratinia A, Caliri A, Tommasi S
Carcinogenesis. 2024; 45(11):868-879.
PMID: 39023127
PMC: 11584291.
DOI: 10.1093/carcin/bgae046.
Mitotic MTH1 inhibitor TH1579 induces PD-L1 expression and inflammatory response through the cGAS-STING pathway.
Shen J, Guillen Mancina E, Chen S, Manolakou T, Gad H, Berglund U
Oncogenesis. 2024; 13(1):17.
PMID: 38796460
PMC: 11127983.
DOI: 10.1038/s41389-024-00518-1.
Visualization of oxidized guanine nucleotides accumulation in living cells with split MutT.
Fujikawa Y, Kawai H, Suzuki T, Kamiya H
Nucleic Acids Res. 2024; 52(11):6532-6542.
PMID: 38738661
PMC: 11194108.
DOI: 10.1093/nar/gkae371.
Biochemical and structural characterization of Fapy•dG replication by Human DNA polymerase β.
Gao S, Oden P, Ryan B, Yang H, Freudenthal B, Greenberg M
Nucleic Acids Res. 2024; 52(9):5392-5405.
PMID: 38634780
PMC: 11109955.
DOI: 10.1093/nar/gkae277.
Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity.
Kang N, Ma J, Hu Y, Di R, Wang L, Zhang X
Pharmaceuticals (Basel). 2024; 17(3).
PMID: 38543077
PMC: 10974945.
DOI: 10.3390/ph17030291.
Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability.
Ye M, Fang Y, Chen L, Song Z, Bao Q, Wang F
Nat Commun. 2024; 15(1):2377.
PMID: 38493213
PMC: 10944511.
DOI: 10.1038/s41467-024-46572-6.
The potential of aryl hydrocarbon receptor as receptors for metabolic changes in tumors.
Wang Z, Zhang Y, Liao Z, Huang M, Shui X
Front Oncol. 2024; 14:1328606.
PMID: 38434684
PMC: 10904539.
DOI: 10.3389/fonc.2024.1328606.
Targeting the nucleic acid oxidative damage repair enzyme MTH1: a promising therapeutic option.
Ding Y, Liu Q
Front Cell Dev Biol. 2024; 12:1334417.
PMID: 38357002
PMC: 10864502.
DOI: 10.3389/fcell.2024.1334417.
Chromosome 8p engineering reveals increased metastatic potential targetable by patient-specific synthetic lethality in liver cancer.
Huth T, Dreher E, Lemke S, Fritzsche S, Sugiyanto R, Castven D
Sci Adv. 2023; 9(51):eadh1442.
PMID: 38134284
PMC: 10745716.
DOI: 10.1126/sciadv.adh1442.